Related Experiment Video
Updated: Mar 1, 2026
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Pancreatic cancer heterogeneity and response to Mek inhibition
K Pedersen1, F Bilal1,2,3, C Bernadó Morales1,2
1Preclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Abstract:
Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer (PC) has not yet translated into effective treatments. Many promising drugs have failed in the clinic, highlighting the need for better preclinical models to assess drug efficacy and characterize mechanisms of resistance. Using different experimental models, including patient-derived xenografts (PDXs), we gauged the efficacy of therapies aimed at two hallmark lesions of PCs: activation of signaling pathways by oncogenic KRAS and inactivation of tumor-suppressor genes. Although the drug targeting inactivation of tumor suppressors by DNA methylation had little effect, the inhibition of Mek, a K-Ras effector, in combination with the standard of care (chemotherapy consisting of gemcitabine/Nab-paclitaxel), reduced the growth of three out of five PC-PDXs and impaired metastasis. The two least responding PC-PDXs were composed of genetically diverse cells, which displayed sensitivities to the Mek inhibitor differing by >10-fold. Unexpectedly, our analysis of this genetic diversity unveiled different KRAS mutations. As mutation in KRAS occurs early during progression, this heterogeneity may reflect the simultaneous appearance of different malignant cellular clones or, alternatively, that cells containing two mutations of KRAS are selected during tumor evolution. In vitro and in vivo analyses indicated that the intratumoral heterogeneity, along with the selective pressure imposed by the Mek inhibitor, resulted in rapid selection of resistant cells. Together with the gemcitabine/Nab-paclitaxel backbone, Mek inhibition could be effective in treatment of PC. However, resistance because of intratumoral heterogeneity is likely to develop frequently, pointing to the necessity of identifying the factors and mechanisms of resistance to further develop this therapy.
Insights
Mek inhibition combined with chemotherapy shows promise for pancreatic cancer (PC) treatment, reducing tumor growth and metastasis in patient-derived models. However, KRAS mutation-driven heterogeneity can lead to rapid resistance, necessitating further research into resistance mechanisms.
Area of Science:
- Oncology
- Cancer Biology
- Translational Research
Background:
- Pancreatic cancer (PC) treatment remains challenging despite advances in understanding its progression.
- Existing preclinical models often fail to predict clinical drug efficacy, necessitating improved models like patient-derived xenografts (PDXs).
- Targeting KRAS signaling and tumor suppressor inactivation are key strategies in PC therapy development.
Purpose of the Study:
- To evaluate the efficacy of targeting KRAS effectors and tumor suppressor inactivation in preclinical models of pancreatic cancer.
- To investigate the role of intratumoral heterogeneity and KRAS mutations in treatment response and resistance.
- To assess the potential of Mek inhibition combined with standard chemotherapy for PC treatment.
Main Methods:
- Utilized patient-derived xenografts (PDXs) as experimental models for pancreatic cancer.
- Administered Mek inhibitors in combination with standard chemotherapy (gemcitabine/Nab-paclitaxel).
- Analyzed genetic diversity, KRAS mutations, and in vitro/in vivo responses to Mek inhibition.
Main Results:
- Mek inhibition plus standard chemotherapy reduced tumor growth in 3 out of 5 PC-PDXs and impaired metastasis.
- PC-PDXs with greater genetic diversity showed significantly varied sensitivity to Mek inhibitors.
- Identified distinct KRAS mutations within heterogeneous tumors, suggesting clonal evolution or simultaneous clone emergence.
- Intratumoral heterogeneity and Mek inhibition led to rapid selection of resistant cells.
Conclusions:
- Mek inhibition, combined with gemcitabine/Nab-paclitaxel, offers a potential therapeutic strategy for pancreatic cancer.
- Intratumoral heterogeneity, particularly diverse KRAS mutations, is a significant driver of rapid treatment resistance.
- Further research is crucial to identify resistance factors and mechanisms to optimize Mek inhibitor-based therapies for PC.
